Amarin Corp ADR
(NQ:
AMRN
)
0.5828
+0.0028 (+0.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amarin Corp ADR
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
April 17, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today
April 04, 2023
Macro headwinds are weighing on risk-laden biotech stocks today.
Via
The Motley Fool
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
April 04, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
March 16, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Plc (AMRN) Q4 2022 Earnings Call Transcript
March 01, 2023
AMRN earnings call for the period ending December 31, 2022.
Via
The Motley Fool
Earnings Scheduled For March 1, 2023
March 01, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
Via
Benzinga
Amarin Announces Board Departures
March 06, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
March 06, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome
March 06, 2023
Via
Benzinga
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
March 05, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 01, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Sarissa Capital Wins Proxy Contest Against Amarin by Huge Landslide
February 28, 2023
From
Sarissa Capital Management LP
Via
Business Wire
Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
February 28, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
February 28, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Sets the Record Straight on Sarissa’s Latest Misstatements
February 27, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC
February 27, 2023
Presentations on Additional REDUCE-IT® Sub-Population, In-Vitro Data on EPA to Be Featured at the Congress
From
Amarin Corporation plc
Via
GlobeNewswire
Sarissa Capital Condemns Amarin Board for Frontrunning Results of Proxy Contest With Egregious Equity Grants to Executives
February 27, 2023
From
Sarissa Capital Management LP
Via
Business Wire
Amarin to Present at Cowen's 43rd Annual Health Care Conference
February 22, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Sarissa Capital Reminds Amarin Shareholders Today Is the Last Day to Vote “FOR” Change
February 21, 2023
From
Sarissa Capital Management LP
Via
Business Wire
Amarin to Report Fourth Quarter and Full Year 2022 Financial Results And Host Conference Call on March 1st, 2023
February 21, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Sarissa Capital Urges Amarin Shareholders to Vote “FOR” Necessary Change
February 20, 2023
From
Sarissa Capital Management LP
Via
Business Wire
Amarin Urges Shareholders to Vote “Against” Sarissa’s Harmful Proposals at Upcoming General Meeting – IT HAS NO PLAN, NO NEW IDEAS AND AN UNDERQUALIFIED SLATE
February 17, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Sarissa Capital Urges Amarin Shareholders to Vote for Change and Remake Amarin for Shareholders
February 17, 2023
From
Sarissa Capital Management LP
Via
Business Wire
Sarissa Capital Blasts Amarin’s Repeated False Statements; Clearly Amarin Will Say Anything to Keep Sarissa Off the Board
February 16, 2023
From
Sarissa Capital Management LP
Via
Business Wire
Leading Independent Proxy Firm ISS Joins Glass Lewis in Recommending that Amarin Shareholders Vote “AGAINST” Sarissa’s Value-Destructive Proposals
February 16, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Clearly and Definitively Instructed Registrar to Accept ALL Submitted Proxy Cards
February 16, 2023
Sarissa Issued its False Release Hours After Receiving Confirmation That All Proxy Cards Were Being Accepted
From
Amarin Corporation plc
Via
GlobeNewswire
Sarissa Capital Uncovers That Amarin’s Registrar Had Not Been Instructed to Accept Blue Proxy Cards Even Though Legally Required to Do So
February 15, 2023
From
Sarissa Capital Management LP
Via
Business Wire
Sarissa Capital Disappointed That Amarin Webcast Continues Board’s Defense of Poor Results and Lack of Accountability
February 14, 2023
From
Sarissa Capital Management LP
Via
Business Wire
Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Amarin Shareholders Vote “AGAINST” All of Sarissa’s Proposals
February 13, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Sarissa Capital Warns of Amarin’s Expensive Attempts to Switch Votes by Inundating Shareholders With White Proxy Cards
February 13, 2023
From
Sarissa Capital Management LP
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.